Related Experiment Video

Updated: May 26, 2026

Single-port Non-liposuction Endoscopic Axillary Lymph Node Dissection in Breast Cancer Surgery
11:49

Single-port Non-liposuction Endoscopic Axillary Lymph Node Dissection in Breast Cancer Surgery

Published on: April 3, 2026

No correlation between plasma D-dimer levels and lymph node involvement in operable breast cancer

Vittorio Fregoni, Lea Regolo, Gian Antonio Da Prada

    Breast (Edinburgh, Scotland)
    |December 31, 2011
    PubMed
    Summary

    No abstract available in PubMed .

    More Related Videos

    Integrating Augmented Reality Tools in Breast Cancer Related Lymphedema Prognostication and Diagnosis
    06:03

    Integrating Augmented Reality Tools in Breast Cancer Related Lymphedema Prognostication and Diagnosis

    Published on: February 6, 2020

    Related Experiment Videos

    Last Updated: May 26, 2026

    Single-port Non-liposuction Endoscopic Axillary Lymph Node Dissection in Breast Cancer Surgery
    11:49

    Single-port Non-liposuction Endoscopic Axillary Lymph Node Dissection in Breast Cancer Surgery

    Published on: April 3, 2026

    Integrating Augmented Reality Tools in Breast Cancer Related Lymphedema Prognostication and Diagnosis
    06:03

    Integrating Augmented Reality Tools in Breast Cancer Related Lymphedema Prognostication and Diagnosis

    Published on: February 6, 2020

    Related Concept Videos

    Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies01:20

    Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

    The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...

    Articles linked to this work by shared authors, journal, and citation graph.

    Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trial.

    The Lancet. Oncology·2026

    Development and Preliminary Validation of a Tool to Assess Barriers and Facilitators to Participation in Adjuvant Endocrine Therapy Switch Trials.

    Current oncology (Toronto, Ont.)·2026

    Risk stratification and relapse pattern in triple-negative breast cancer with pathological complete response after neoadjuvant treatment: the European GAMBIT real-world study.

    Nature communications·2026

    Budget impact analysis of Oncotype DX® multigenic prognostic test in patients with early breast cancer in Italy.

    The European journal of health economics : HEPAC : health economics in prevention and care·2026

    Real-world effectiveness of CDK4/6 inhibitors in older patients with HR+/HER2- advanced breast cancer: a sub-analysis of the multicenter, PALMARES-2 study.

    Breast (Edinburgh, Scotland)·2026

    Integrating PIK3CA Testing into Clinical Practice for Advanced HR+/HER2- Breast Cancer: An Expert Consensus.

    Breast (Edinburgh, Scotland)·2026

    Availability and public reimbursement of early breast cancer care across European expert centres: a PORTRAIT from an EUSOMA initiative.

    Breast (Edinburgh, Scotland)·2026

    The landscape of clonal hematopoiesis of indeterminate potential in long-term breast cancer survivors.

    Breast (Edinburgh, Scotland)·2026

    Impact of depression on treatment response and survival among patients with breast cancer: A multi-institutional retrospective cohort study.

    Breast (Edinburgh, Scotland)·2026

    Residual disease after radiologically complete vacuum-assisted breast excision in patients with ductal carcinoma in situ: A systematic review and meta-analysis.

    Breast (Edinburgh, Scotland)·2026

    Artificial intelligence for predicting pathological complete response to neoadjuvant therapy in triple-negative breast cancer: A systematic review and meta-analysis.

    Breast (Edinburgh, Scotland)·2026

    Antibody-drug conjugates beyond HER2: Translating evidence into practice for HR+ HER2-negative and triple-negative metastatic breast cancer.

    Breast (Edinburgh, Scotland)·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us